Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania
Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )
8 Mar 2023

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou
Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )
19 Feb 2023

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC

Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile
3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC ( Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile )
19 Feb 2023

Plasma miR371 detects MRD and early relapse of germ cell tumours

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada
Plasma miR371 detects MRD and early relapse of germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )
19 Feb 2023

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )
18 Feb 2023

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )
17 Feb 2023

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma

Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada
JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma ( Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada )
16 Feb 2023

Safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma

Dr Talal El Zarif - Dana-Farber Cancer Institute, Boston, USA
Safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma ( Dr Talal El Zarif - Dana-Farber Cancer Institute, Boston, USA )
16 Feb 2023

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer

Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain
HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer ( Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain )
7 Feb 2023